A biotechnology company focused on developing reliable PZA susceptibility testing method and next-generation PZA drug to shorten treatment, PZA Innovation LLC is structured around developing reliable pyrazinamide, a first-line tuberculosis drug, susceptibility.Principals of the firm have sterilising activity in vivo using reverse engineering tto determine the conditions under which pyrazinamide is active in vitro. That is, pyrazinamide acts on the living environment of mycobacterium tuberculosis in the host. Working in collaboration with two institutes, the objective is to address systemic issues and limitations in current methods -- an advancement that promises to enhance TB treatment by providing patients with the most effective treatment and curbing TB drug resistance.
